Plain-English translation of NCT04698564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a specialized type of MRI scan called metabolic imaging to see if it can safely and effectively detect prostate cancer in men who show signs of the disease. This new imaging approach looks at how cancer cells use energy differently than healthy cells, which may help doctors spot cancer more accurately.
Current ways of detecting and assessing prostate cancer have limitations. Researchers want to know if this new metabolic imaging approach could be a safer, more accurate tool to help diagnose cancer and predict which patients are at higher risk—potentially improving treatment decisions.
If you qualify, you would undergo a specialized metabolic MRI scan while you are in the hospital being treated or evaluated for prostate cancer. The scan itself works similarly to a standard MRI but uses a special form of energy to look at how cancer cells function. This is a small pilot study designed mainly to confirm that the scan is safe to perform in men with prostate cancer.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Maryland, Baltimore
Enrollment target
~4 participants
Started
December 2020
Primary completion
December 2025
Age range
40 Years – 80 Years
Sex
Male only
Last updated on clinicaltrials.gov in July 2026.